Skip to main content
SpringerLink
Log in

Eltrombopag For Immune Thrombocytopenic Children in a Single Region

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Objective Child patients of chronic thrombocytopenic purpura with severe and resistant thrombocytopenia were evaluated to observe whether their clinical or laboratory states improve by one of the thrombomimetic therapeutic agent called Eltrombopag as in adults in a single center of different country from previous studies. Materials and Methods Nineteen patients with chronic immune thrombocytopenia were treated with Eltrombopag to dose in international guidelines. Results Approximately half (11/19:58%) of the patients benefitted from the treatment with Eltrombopag either by an increase of platelet levels at safe levels with a decrease in the frequency of bleedings which needed rescue treatment. Conclusion Thrombomimetic treatment options have strengthened the clinician’s hand where the regular treatment options became insufficient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ramaswamy K et al (2014) Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr 165(3):600–605

    Article  CAS  Google Scholar 

  2. Burness Celeste B, Keating GM, Garnock-Jones KP (2016) Eltrombopag: a review in paediatric chronic immune thrombocytopenia. Drugs 76(8):869–878

    Article  CAS  Google Scholar 

  3. Bolton-Maggs Paula (2003) Severe bleeding in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 25:S47–S51

    Article  Google Scholar 

  4. Grainger JD et al (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386(10004):1649–1658

    Article  CAS  Google Scholar 

  5. Ali S et al (2017) Eltrombopag for secondary failure of platelet recovery post‐allogeneic hematopoietic stem cell transplant in children. Pediatr Transplant 21(6). https://doi.org/10.1111/petr.13017

    Article  Google Scholar 

  6. Ma J et al (2016) Clinical study of pulsed high-dose dexamethasone treatment in 38 children with primary immune thrombocytopenic purpura. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 37(10):912–915

    CAS  PubMed  Google Scholar 

  7. Naithani Rahul, Sachdev Mansi, Uttam Rajiv (2016) Successful use of eltrombopag in a child with hurler syndrome after haploidentical hematopoietic stem cell transplantation. J Pediatr Hematol/Oncol 38(2):163–164

    Article  Google Scholar 

  8. Özdemirkıran F et al (2015) Eltrombopag for the treatment of immune thrombocytopenia: the aegean region of turkey experience. Turkish J Hematol 32(4):323

    Article  Google Scholar 

  9. Grainger JD, Thind S (2017) A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia. Pediatr Hematol Oncol 34(2):1–17

    Article  Google Scholar 

  10. Elgebaly AS et al (2016) Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clinic Appl Thrombosis/Hemostasis 23(8):928–937

    Article  Google Scholar 

  11. Neunert C et al (2016) Thrombopoiet in receptor agonist use in children: data from the pediatric ITP consortium of North America ICON2 study. Pediatr Blood Cancer 63(8):1407–1413

    Article  CAS  Google Scholar 

  12. Gerrits AJ et al (2015) Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrichsyndrome/X-linkedthrombocytopenia. Blood 126(11):1367–1378

    Article  CAS  Google Scholar 

  13. Bussel JB et al (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2(8):e315–e325

    Article  Google Scholar 

  14. Mazzucconi MG et al (2017) Tpo‐ras in pitp: description of a case series and analysis of predictive factors for response. Eur J Haematol 98(3):242–249

    Article  Google Scholar 

  15. Suntsova EV et al (2017) Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura. Int J Hematol 105(6):841–848

    Article  CAS  Google Scholar 

  16. Wang X-L, Li A-M (2016) Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review. Blood Coagul Fibrinol 27(7):825–827

    Article  Google Scholar 

  17. Garzon AM, Mitchell WB (2015) Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Frontiers Pediatr 3:70

    Article  Google Scholar 

  18. Scully M et al (2012) Eltrombopag named patient programme for patients with chronic immune thrombocytopenia. B J Haematol 157(2):259–260

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology, Çukurova University Medical Faculty, Adana, Turkey

    Göksel Leblebisatan, Yurdanur Kilinc, Metin Cil & İlgen Sasmaz

  2. Adana Numune Research and Education Hospital, Pediatric Hematology-Oncology, Adana, Turkey

    Ayse Ozkan

Authors
  1. Göksel Leblebisatan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yurdanur Kilinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Metin Cil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. İlgen Sasmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ayse Ozkan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Göksel Leblebisatan.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leblebisatan, G., Kilinc, Y., Cil, M. et al. Eltrombopag For Immune Thrombocytopenic Children in a Single Region. Indian J Hematol Blood Transfus 34, 707–710 (2018). https://doi.org/10.1007/s12288-018-0928-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-018-0928-y

Keywords

Search

Navigation